Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection

[1]  T. Schlake,et al.  Developing mRNA-vaccine technologies , 2012, RNA biology.

[2]  A. Thess,et al.  Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect , 2012, The journal of gene medicine.

[3]  S. Gubbins,et al.  Immune Responses in Pigs Vaccinated with Adjuvanted and Non-Adjuvanted A(H1N1)pdm/09 Influenza Vaccines Used in Human Immunization Programmes , 2012, PloS one.

[4]  K. Lindblade,et al.  A distinct lineage of influenza A virus from bats , 2012, Proceedings of the National Academy of Sciences.

[5]  Yan Zhou,et al.  Pandemic H1N1 influenza virus-like particles are immunogenic and provide protective immunity to pigs. , 2012, Vaccine.

[6]  J. Oxford,et al.  Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans , 2012, Nature Medicine.

[7]  K. Ljungberg,et al.  Intradermal Electroporation of Naked Replicon RNA Elicits Strong Immune Responses , 2012, PloS one.

[8]  D. Atanackovic,et al.  Messenger RNA vaccination in NSCLC: Findings from a phase I/IIa clinical trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  U. Steiner,et al.  Final analysis of a phase I/IIa study with CV9103, an intradermally administered prostate cancer immunotherapy based on self-adjuvanted mRNA. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Fotin‐Mleczek,et al.  Messenger RNA-based Vaccines With Dual Activity Induce Balanced TLR-7 Dependent Adaptive Immune Responses and Provide Antitumor Activity , 2011, Journal of immunotherapy.

[11]  A. Fauci,et al.  Induction of unnatural immunity: prospects for a broadly protective universal influenza vaccine , 2010, Nature Medicine.

[12]  Margaret A. Liu,et al.  Immunologic basis of vaccine vectors. , 2010, Immunity.

[13]  M. Beer,et al.  New real-time reverse transcriptase polymerase chain reactions facilitate detection and differentiation of novel A/H1N1 influenza virus in porcine and human samples. , 2010, Berliner und Munchener tierarztliche Wochenschrift.

[14]  R. Webster,et al.  Cross-Reactive Neutralizing Antibodies Directed against Pandemic H1N1 2009 Virus Are Protective in a Highly Sensitive DBA/2 Mouse Influenza Model , 2010, Journal of Virology.

[15]  A. García-Sastre,et al.  PB1-F2 Expression by the 2009 Pandemic H1N1 Influenza Virus Has Minimal Impact on Virulence in Animal Models , 2010, Journal of Virology.

[16]  H. Ehrlich,et al.  A Whole Virus Pandemic Influenza H1N1 Vaccine Is Highly Immunogenic and Protective in Active Immunization and Passive Protection Mouse Models , 2010, PloS one.

[17]  M. Beer,et al.  Pathogenesis and transmission of the novel swine-origin influenza virus A/H1N1 after experimental infection of pigs. , 2009, The Journal of general virology.

[18]  N. Cox,et al.  Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. , 2009, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[19]  I. Stephenson,et al.  Influenza vaccines for the future , 2009 .

[20]  T. Strutt,et al.  Tc17, a Unique Subset of CD8 T Cells That Can Protect against Lethal Influenza Challenge1 , 2009, The Journal of Immunology.

[21]  Volker Brauer,et al.  Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels , 2009, Proceedings of the National Academy of Sciences.

[22]  R. Webster,et al.  The Influenza Virus Enigma , 2009, Cell.

[23]  Arbeitskreis Blut,et al.  Influenza Virus , 2009, Transfusion Medicine and Hemotherapy.

[24]  Rino Rappuoli,et al.  Structure-based antigen design: a strategy for next generation vaccines , 2008, Trends in Biotechnology.

[25]  S. Plotkin,et al.  Vaccines: correlates of vaccine-induced immunity. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  J. Oxford,et al.  Animal models in influenza vaccine testing , 2008, Expert review of vaccines.

[27]  P. Laurent,et al.  Evaluation of the clinical performance of a new intradermal vaccine administration technique and associated delivery system. , 2007, Vaccine.

[28]  A. Osterhaus,et al.  Influenza virus-specific cytotoxic T lymphocytes: a correlate of protection and a basis for vaccine development. , 2007, Current opinion in biotechnology.

[29]  R. Belshe.  Translational Research on Vaccines: Influenza as an Example , 2007, Clinical pharmacology and therapeutics.

[30]  Rino Rappuoli,et al.  Vaccine manufacturing: challenges and solutions , 2006, Nature Biotechnology.

[31]  Deborah M. Brown,et al.  CD4 T Cell-Mediated Protection from Lethal Influenza: Perforin and Antibody-Mediated Mechanisms Give a One-Two Punch1 , 2006, The Journal of Immunology.

[32]  Paul G Thomas,et al.  Influenza and the challenge for immunology , 2006, Nature Immunology.

[33]  G. Forde,et al.  Rapid-response vaccines—does DNA offer a solution? , 2005, Nature Biotechnology.

[34]  S. De Clercq,et al.  Efficacy of vaccination of pigs with different H1N1 swine influenza viruses using a recent challenge strain and different parameters of protection. , 2001, Vaccine.

[35]  A. Osterhaus,et al.  Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine‐induced antibody response to this strain in the elderly , 2000, Journal of medical virology.

[36]  J. Yewdell,et al.  MHC affinity, peptide liberation, T cell repertoire, and immunodominance all contribute to the paucity of MHC class I-restricted peptides recognized by antiviral CTL. , 1997, Journal of immunology.

[37]  M. Marschall,et al.  Comparative analysis of six European influenza vaccines , 1996, European Journal of Clinical Microbiology and Infectious Diseases.

[38]  J. Ulmer,et al.  Heterologous protection against influenza by injection of DNA encoding a viral protein. , 1993, Science.

[39]  H. Waldmann,et al.  Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo , 1984, Nature.

[40]  A. McMichael,et al.  Cytotoxic T-cell immunity to influenza. , 1983, The New England journal of medicine.

[41]  L. Reed,et al.  A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS , 1938 .

[42]  Richard,et al.  Tc 17 , a Unique Subset of CD 8 T Cells That Can Protect against Lethal Influenza Challenge 1 , 2009 .

[43]  S. Pascolo.  Vaccination with messenger RNA (mRNA). , 2008, Handbook of experimental pharmacology.

[44]  S. Plotkin.  Correlates of Vaccine-Induced Immunity , 2008 .

[45]  S. Pascolo.  Vaccination with messenger RNA. , 2006, Methods in molecular medicine.

[46]  Robert T. Chen,et al.  Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002 , 2002 .

[47]  J. Nietupski,et al.  CHALLENGES AND SOLUTIONS , 2001 .

[48]  H. Rammensee,et al.  In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. , 2000, European journal of immunology.

[49]  C W Potter,et al.  Determinants of immunity to influenza infection in man. , 1979, British medical bulletin.